Cerberus Therapeutics Appoints Dr. David Hafler to its Scientific Advisory Board

CAMBRIDGE, Mass., December 8, 2022 – Cerberus Therapeutics, Inc., an early-stage biotechnology company focused on development of proprietary nanobody-based platforms to create novel immunotherapeutics, today announced the appointment of Dr. David Hafler, a world-renowned expert on multiple sclerosis (“MS”) and Chair of the Department of Neurology at Yale School of Medicine, to its Scientific Advisory Board.

“Dr. Hafler has been a pioneer in the understanding and treatment of MS through his lab at Yale. He is an authority on the mechanisms of autoimmunity and inflammatory diseases of the central nervous system,” said Dr. Hidde Ploegh, Chair of Scientific Advisory Board and Co-Founder of Cerberus Therapeutics. “I am very excited to work with Dr. Hafler to further development of our antigen specific tolerance platform.”

About Cerberus Therapeutics

Founded in 2021 by Novalia Pishesha, Ph.D., Prof. Hidde Ploegh, Ph.D. and Prof. Harvey Lodish, Ph.D., Cerberus Therapeutics’ nanobody-based technology comprises two distinct platforms: one that targets autoimmunity and one aimed at infectious disease. Leveraging the unique biochemical properties and excellent targeting capabilities of alpaca-derived nanobodies (variable domains of heavy chain-only antibodies), Cerberus’ technology has the potential to reset the immune system and have it rewire itself for therapeutic gain.

Cerberus Contact:
Xiaohong Sang